Market revenue in 2020 | USD 404.2 million |
Market revenue in 2028 | USD 641.8 million |
Growth rate | 6% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | CNS Cancer |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 49.31% in 2020. Horizon Databook has segmented the Argentina central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
According to a WHO report, there is high prevalence of mental illness in Argentina with 25% of all Argentines experiencing some form of mental illness at some point of their lives. The report also indicates that depression is the second leading cause of disability in the country.
However, high treatment cost for mental illness impedes market growth. Moreover, there is a significant presence of neurological diseases in the country. For instance, Alzheimer’s is the most common form of dementia and is the fifth leading cause of death, affecting more than 300,000 individuals in the country.
The recommended drugs for the treatment of specific dementias in Argentina include memantine, rivastigmine, galantamine, and donepezil. However, many other non reimbursable drugs are often used to treat patients with cognitive impairment, resulting in higher out-of-pocket expenses.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Argentina central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account